Outsourced Pharma Capacity Update Videos - Large Molecule
-
Cytovance Biologics Capabilities Update March 2026: Large Molecule
3/17/2026
How a seasoned development and manufacturing team blends technical depth, reliability, and flexible support to advance large‑molecule programs amid shifting timelines, costs, and regulatory demands.
-
Fujifilm Biotechnologies Capabilities Update March 2026: Large Molecule
3/10/2026
An overview of manufacturing strategies and scaling options shows how aligned systems, smart planning, and flexible models support biologics from early development to commercialization.
-
ProBio Capabilities Update March 2026: Large Molecule
3/10/2026
A new Center of Excellence expands capacity for genetic‑medicine programs with upgraded facilities, streamlined workflows, and early‑stage services that support readiness for PD and IND milestones.
-
Boehringer Ingelheim Capabilities Update March 2026: Large Molecule
3/10/2026
Integrated culture and fermentation systems streamline development, improve scalability, and strengthen continuity throughout the lifecycle of complex biopharmaceutical programs.
-
OPCU October 2025: Large Molecule
10/16/2025
Advance your biotherapeutic with a trusted global CDMO partner offering end-to-end development and manufacturing, supported by state-of-the-art facilities and a commitment to your success.
-
Nanoform Capacity Update October 2025: Large Molecule
10/16/2025
Sergie Letser, Deputy CCO, presents an overview of Nanoform’s novel large molecule nanoforming technology capabilities and current capacity.
-
Cytovance Biologics Capacity Update October 2025: Large Molecule
10/16/2025
Partner with a U.S.-based, trusted CDMO large enough to support every stage of your program, yet agile enough to deliver the dedicated care your project deserves.
-
From Concept To Market: Mammalian Protein Development And Manufacturing
10/16/2025
With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.
-
AGC Biologics Capacity Update October 2025: Large Molecule
10/16/2025
Michael Brotz provides an in-depth look at our Seattle site and the unique capabilities of the facility, including its single-use and stainless-steel capacity, new manufacturing lines, and more.
-
Samsung Biologics Capacity Update October 2025: Large Molecule
10/16/2025
Accelerate your cancer therapy development with patient-derived organoids — high-fidelity models that enhance translational confidence, streamline discovery, and bring promising treatments to the clinic faster.